WAINUAtm (eplontersen) Granted First-Ever Regulatory Approva

WAINUAtm (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

WAINUAtm (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , United States , American , America , Michaelj Polydefkis , Isabelle Lousada , Columbia University Irving Medical Center , Product Service , Amyloidosis Research Consortium , Commission Implementing Decision , Journal Of The American Medical Association , Astrazeneca , Ionis Pharmaceuticals , European Commission , European Parliament , Drug Administration , Granted First Ever Regulatory Approval , Adults With Polyneuropathy , Hereditary Transthyretin Mediated , Neuropathy Impairment Score , Norfolk Quality , Life Questionnaire Diabetic Neuropathy , American Medical Association , Johns Hopkins University School , Executive Vice President , Biopharmaceuticals Business Unit , Latin America , Orphan Drug Designation , Serum Vitamin , Recommended Supplementation , Prescribing Information , Rare Diseases , Hereditary Transthyretin Amyloidosis With , Annual Report , Clin Risk , Global Phase , Antisense Oligonucleotide , Hereditary Transthyretin Mediated Amyloid , Neurol Neurosurg , Open Label Phase , University Irving Medical Center , Drug Reduces Death , Underdiagnosed Form , Heart Failure ,